Skip to content

Tonix Pharmaceuticals Logo

  • About
    • Leadership
      • Executive Team
      • Board of Directors
    • Facilities
  • Therapeutic Areas Overview
    • Central Nervous System
      • Fibromyalgia
      • Migraine
    • Immunology
      • Organ Transplant Rejection
      • Gastro-Intestinal Cancers
    • Infectious Disease
      • Lyme Disease
      • Mpox (Monkey Pox)
      • Smallpox
    • Rare Disease
      • Prader-Willi Syndrome
  • Pipeline
    • Central Nervous System
      • TNX-102 SL
    • Immunology
      • TNX-1500
      • TNX-1700
    • Infectious Disease
      • TNX-4800
      • TNX-801
      • TNX-4200 CD45
    • Rare Disease
      • TNX-2900
    • Expanded Access Policy
  • Medicines
  • Clinical Trials
  • News & Events
    • Press Releases
    • Tonix in the News
    • Tonix Sponsored News
    • Investor Presentations
    • Scientific Presentations
    • IR Events
    • Op-eds
  • Investors
    • News & Events
    • Presentations
      • Investor Presentations
      • Scientific Presentations
      • Program Specific Presentations
      • Conference Materials
    • Multimedia
    • Financial Info
    • Stock Data
    • SEC Filings
    • Governance
  • Careers
  • Contact Us
June 2023

ASCP 2023: A Randomized Placebo-Controlled Multicenter Trial of Monotherapy with TNX-601 ER (Tianeptine Hemioxalate Extended-Release Tablets) for Treatment of Major Depressive Disorder (MDD)

April 2023

AACR: MDSC-targeted TFF2-MSA Synergizes with PD-1 Blockade Therapy in Advanced Gastric Cancer Models

April 2023

AACR: MDSC-Targeted mTFF2-MSA (mTNX-1700) Suppresses Tumor Growth and Increases Survival in Anti-PD-1 Treated MC38 and CT26.wt Murine Colorectal Cancer Models

April 2023

TNX-801: A Novel Mpox Vaccine: Live, Replicating, Attenuated Orthopoxvirus (Horsepox) Vaccine

April 2023

The Development of Horsepox Virus as a Vaccine Platform: Evaluation of TNX-1800 as a SARS-CoV-2 Vaccine

March 2023

The 5th International Congress on Controversies in Fibromyalgia

March 2023

Efficacy and Safety of TNX-102 SL (Sublingual Cyclobenzaprine) for the Treatment of Fibromyalgia: Results from the Randomized, Placebo-Controlled RELIEF Trial

March 2023

TNX-2900 — Rare Disease Summit, Philadelphia, 23-March-2023

March 2023

mTFF2-MSA (mTNX-1700) Suppresses Tumor Growth and Increases Survival in an Anti-PD-1 Treated MC38 Colorectal Cancer Model by Targeting MDSCs

February 2023

TNXP Presentation for BIO and Solve ME Event

Posts navigation

Older posts
Newer posts
Sign up for Email Alerts
  • Compliance
  • Privacy Policy
  • Terms of Service
  • Site Map

© 2026 Tonix Pharmaceuticals Holding Corp.